CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 22 enrolled
Drug / intervention
Sildenafil 20 mg tablets +1 moredrug
Likely dose
Sildenafil 20 mg tabletsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02335242
NCT02335242Phase 2Completed

Phase 2 Study of Sildenafil for the Treatment of Lymphatic Malformations

Stanford University·interventional·Posted Jan 9, 2015·Updated Nov 17, 2022

In Brief

A Phase 2 clinical trial evaluating Sildenafil 20 mg tablets and Placebo tablets (resembling Revatio) for Lymphatic Malformations and Lymphatic Diseases. Completed, enrolled 22 participants across 3 sites.

Detailed Summary

A Phase 2 study to evaluate safety and efficacy of sildenafil taken orally to improve or resolve lymphatic malformations in children. Subjects may receive either placebo or treatment in an oral dosage with an open label extension for subjects who received placebo. The study treatment assignment will be randomized in a double blind fashion. MRI examination will evaluate change in lesion volume due to treatment. Other safety and efficacy measures will be taken through the 32-week study duration. Funding Source - FDA OOPD

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJan 9, 2015
Enrollment StartMay 23, 2015
Primary CompletionMar 30, 2021
TodayJul 2, 2026
Enrollment to primary: 5.9 yearsPosted 11.5 years ago

Interventions

Sildenafil 20 mg tabletsdrug

Placebo tablets (resembling Revatio)other